A preparation of alprostadil (prostaglandin E1) plus syringe and diluent (Caverject - Upjohn) has recently been licensed in the UK for the treatment of erectile impotence by injection into the corpus cavernosum. How does it compare with papaverine, which, though unlicensed for this indication, has been the mainstay of drug treatment for impotence?
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.